OPKO Health (OPK) Reports Research Collaboration with Radboud University Medical Center

January 12, 2018 8:06 AM EST

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

OPKO Health, Inc. (NASDAQ: OPK) announces today that GeneDx, Inc., a subsidiary of OPKO’s BioReference Laboratories, has entered into a research collaboration with the Radboud University Medical Center, Nijmegen, Netherlands. Through the agreement, GeneDX and Radboud aim to identify novel genes and pathways to help understand the causes, clinical characteristics, and eventual management of human genetic diseases. Additionally, the project will improve informatics and statistical methods to robustly and rapidly diagnose patients with genetic conditions.

GeneDx, an industry leader in whole exome sequencing (WES), launched its WES program in 2011. Over the past five years, work at GeneDx has helped discover or contribute to the phenotypic understanding of dozens of novel disease genes associated with developmental delay or intellectual disability. With this newest research collaboration, the study cohort will expand with approximately 3,000 additional cases* from Radboud, thus creating the largest combined data set of neurodevelopmental exomes for genetic analysis and discovery.

“The opportunity to collaborate with Radboud is yet another exciting advancement for our WES program,” said Kyle Retterer, Chief Innovation Officer of GeneDx and co-principal investigator for the collaboration. “The shared combination of our data summaries and analytical tools to conduct meta-analyses of GeneDx and Radboud datasets will help us better understand the genetic basis of neurological health and disease.”

Radboud’s key strength is the combination of medical life sciences and clinical practice. The medical center has an infrastructure comprised of three research institutes and state of the art technology centers. The center’s scientists perform cross disciplinary research regarding 18 clinically relevant research themes.

“With this collaboration we hope to expand our knowledge of neurodevelopmental disorders and provide better diagnoses to our patients,” said Christian Gilissen, Associate Professor at the Radboud University Medical Center and principal investigator for the collaboration. “We are pleased to work with GeneDX on this project.”

To learn more about Radboud University Medical Center research please visit its website at www.radboudumc.nl/research. For GeneDx’s complete list of testing options, please visit its website www.genedx.com or email genedx@genedx.com.

*GeneDx will not share individual patient level data as part of this collaboration. Additionally, if this research results in publication, GeneDx will only include patients where explicit consent for publication has been obtained.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Management Comments

Related Entities

FDA